Skip to content

Paediatric Use of the Abbott Sensor Based Glucose Monitoring System

Paediatric Use of the Abbott Sensor Based Glucose Monitoring System - an Accuracy Evaluation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03433573
Acronym
PUGS
Enrollment
103
Registered
2018-02-14
Start date
2018-02-16
Completion date
2018-05-11
Last updated
2018-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

Accuracy evaluation of the Abbott Sensor Based Glucose Monitoring System when used by children with diabetes.

Interventions

Subjects will wear the Abbott Sensor Based Glucose Monitoring System and will be asked to perform 4 blood glucose tests per day (pre-meal and before bedtime). Subjects will be asked to scan the sensor when each blood glucose test is performed.

Sponsors

Abbott Diabetes Care
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Age 4-17 years (inclusive). * Have type 1 or type 2 diabetes using insulin administered by injections or continuous subcutaneous insulin infusion (CSII). * Currently testing blood glucose levels at least twice per day. * Each participant has an identified Caregiver aged ≥18 years. * In the investigator's opinion, technically capable of using device (participant and/or caregiver).

Exclusion criteria

* Concomitant disease or condition that may compromise patient safety including and not limited to; cystic fibrosis, severe mental illness, known or suspected eating disorder or any uncontrolled long term medical condition. * Currently prescribed oral steroid therapy for any acute or chronic condition. * Currently receiving dialysis treatment or planning to receive dialysis during the study. * Female participant known to be pregnant. * Participating in another study of a glucose monitoring device or drug that could affect glucose measurements or management. * Currently using a real-time or professional use continuous glucose monitoring (CGM) or FreeStyle Libre device or is planning to use one during the study, and unwilling to stop use of the device during the study. * Known (or suspected) allergy to medical grade adhesives. * In the investigator's opinion the participant or caregiver is unsuitable to participate due to any other cause/reason (both patient and caregiver considered).

Design outcomes

Primary

MeasureTime frameDescription
Point Accuracy Determined as % within Consensus Error Grid Zone AUp to 35 daysPoint accuracy of Sensor based glucose values compared to capillary fingerstick blood glucose, determined as % within Consensus Error Grid Zone A.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026